Friday 4 January 2019

Coronary Artery Bypass Graft Market Expected To Trigger A Revenue Increase To USD 127.6 Million By 2025:Key Participant Medtronic, TERUMO CORPORATION


San Francisco, 03 January, Coronary Artery Bypass Graft (CABG) Market Analysis By Type (Saphenous Vein Grafts, Internal Thoracic Artery Grafts), By Surgical Procedures, By Technology (On-Pump CABG, Off-Pump CABG), And Segment Forecasts, 2018 – 2025

The global coronaryartery bypass graft (CABG) market is expected to reach USD 127.6 million by 2025, according to a new report by Grand View Research, Inc. The market is expected to witness lucrative growth over the forecast period, owing to increasing prevalence of Cardiovascular Diseases (CVDs) such as Coronary Artery Disease (CAD) or Coronary Heart Disease (CHD) coupled with rising geriatric population across the globe.
Favorable reimbursement policies, such as the U.S. Medicare (federal health insurance program) system, Medicaid, and National Health Insurance (NHI) have been a prime growth factor for the CABG market. Medical device companies provide new product platforms, which are covered under reimbursement programs that benefit the patients. Reimbursement services provided by Medicare and other insurers to physicians and hospitals is expected to fuel the demand for the adoption of CABG devices such as catheters, cannulae, retractors, positioners & stabilizers, suction devices, and syringes during the forecast period.
Access Full Research Report On Coronary Artery Bypass Graft (CABG) Market Analysis:

Further Key Findings from the Study Suggest:
·         The saphenous vein grafts segment held a profitable revenue share in 2016 and is anticipated to grow at a significant rate over the forecast period
·         The off-pump CABG segment is anticipated to witness the fastest growth over the forecast period owing to the benefits offered by this technology such as increased safety, effective, reduced chances of bleeding during the surgery, low chances of stroke, low need for blood transfusions, low injury to the heart muscle, and improved quality of life
·         The endoscopic vein harvesting segment is expected to gain the market share over the forecast period as it eliminates the requirement for long incisions associated with open (conventional) harvesting, resulting in reducing the risk of wound infection and other complications, minimizing postoperative pain, and increasing the patient satisfaction level
·         North America is expected to dominate the CABG market during the forecast period, owing to the rising prevalence of CVDs in the U.S. and Canada. In addition, increasing per capita healthcare spending and growing population in the region are expected to spur the growth of this vertical.
·         Some of the key players of this market are Medtronic; TERUMO CORPORATION; Guidant Group; MAQUET Holding B.V. & Co.KG; Vitalitec International, Inc.; Novadaq Technologies Inc.; KARL STORZ GmbH & Co. KG; Edwards Lifesciences; Genesee Biomedical Inc.; and Sorin Group
Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/medical-devices
Grand View Research has segmented the global CABG market on the basis of type, surgical procedure, technology, technique, and region:
CABG Market: Type Outlook (Revenue, USD Million, 2014 - 2025)
·         Saphenous Vein Grafts
·         Internal Thoracic Artery Grafts
·         Other
o    Radial Artery
o    Gastroepiploic Artery
CABG Market: Procedure Outlook (Revenue, USD Million, 2014 - 2025)
·         Single CABG Surgery
·         Double CABG Surgery
·         Triple CABG Surgery
·         Quadruple CABG Surgery
CABG Market: Technology Outlook (Revenue, USD Million, 2014 - 2025)
·         On-Pump CABG
·         Off-Pump CABG
CABG Market: Technique Outlook (Revenue, USD Million, 2014 - 2025)
·         Conventional Vessel Harvesting
·         Endoscopic Vessel Harvesting
CABG Market: Regional Outlook (Revenue, USD Million, 2014 - 2025)
·         North America
o    U.S.
o    Canada
·         Europe
o    Germany
o    UK
·         Asia Pacific
o    Japan
o    China
·         Latin America
o    Brazil
o    Mexico
·         Middle East and Africa (MEA)
o    South Africa

Access Full Press Release of this Report:

About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/





Thursday 3 January 2019

Isothermal Nucleic Acid Amplification Technology Market Likely To Reach A Valuation Of Around USD 4.3 Billion By 2025:Key Participant Eiken Chemical Co. Ltd., Hologic, Inc.


San Francisco, 03 January ,  Isothermal Nucleic Acid Amplification Technology (INAAT) Market Analysis By Product, By Technology (NASBA, HDA, LAMP, SDA, SPIA, NEAR, TMA, RCA, RPA, SMAP2), And Segment Forecasts, 2018 – 2025
The global isothermalnucleic acid amplification technology (INAAT) market is expected to reach USD 4.3 billion by 2025, growing at a CAGR of 11.8%, according to a new report by Grand View Research, Inc. This can be attributed to significant rise in awareness regarding need for rapid and on-time testing for chronic and infectious diseases. Global increase in adoption of INAAT for detection of HIV, hepatitis A & B, and sexually transmitted diseases is considered to be a high impact rendering driver for growth.
Loop-Mediated Isothermal Amplification is one of the most preferred nucleic acid amplification methods because of its ability to provide point of care testing, thus leading to increased adoption. The recently-introduced Nicking Enzyme Amplification Reaction (NEAR) and Helicase-dependent amplification (HDA) technologies are expected to experience exponential growth during the forecast period owing to their patent protection.
In addition, owing to recent epidemics of infectious diseases, such as tuberculosis, Zika virus, and influenza, importance of point of care diagnosis has increased especially in developing countries. This is also anticipated to boost demand for this technology in these regions.
Access Full Research Report On Isothermal Nucleic Acid Amplification Technology (INAAT) Market  Analysis:
www.grandviewresearch.com/industry-analysis/isothermal-nucleic-acid-amplification-technology-inaat-market

Further Key Findings From the Report Suggest:
·         Reagents are expected to be fastest growing products owing to their high usage in all INAAT procedures
·         TMA was identified as the largest technology segment by revenue share in 2016 owing to its high adoption
·         Infectious disease diagnostics is expected to be the fastest growing application owing to development of numerous assays for detection of specific infectious diseases
·         Hospitals dominated the end user segment in 2016 with the largest share and are expected to be continue dominance over the forecast period owing to the high usage of INAAT in hospitals globally
·         North America held the largest share of the global market in 2016, and the U.S. held the largest revenue share in the region owing to rise in infectious diseases, availability of government funds, prevalence of cancer, application of MDx in cancer screening & genetic disorders, and self-monitoring techniques
·         The molecular diagnostics industry in Asia Pacific is projected to witness substantial growth over the next decade due to various developments in major economies, especially in the NASBA, NEAR, and HDA technology segments
·         Some of the key players in the INAAT market include Alere; bioMerieux SA; Eiken Chemical Co. Ltd.; Hologic, Inc. (Gen-Probe); Lucigen; QIAGEN; Quidel Corporation; ThermoFisher Scientific; and Becton, Dickinson & Company
·         Major players have been engaging in numerous strategic initiatives such as mergers and acquisitions to increase global presence and improve market share.
Browse More Reports Of This Category By Grand View Research At:  www.grandviewresearch.com/industry/clinical-diagnostics

Grand View Research has segmented the global INAAT market on the basis of product, technology, application, end-use, and region:
Isothermal Nucleic Acid Amplification By Product Outlook (Revenue, USD Million, 2014 - 2025)
·         Instrument
·         Reagent
Isothermal Nucleic Acid Amplification By Technology Outlook (Revenue, USD Million, 2014 - 2025)
·         NASBA
·         HDA
·         LAMP
·         SDA
·         SPIA
·         NEAR
·         TMA
·         RCA
·         RPA
·         SMAP2
·         Others
Isothermal Nucleic Acid Amplification By Application Outlook (Revenue, USD Million, 2014 - 2025)
·         Blood screening
·         Infectious disease diagnostics
·         Cancer
·         Others
Isothermal Nucleic Acid Amplification By End Use Outlook (Revenue, USD Million, 2014 - 2025)
·         Hospitals,
·         Central and reference labs
·         Others
Regional Outlook (Revenue, USD Million, 2014 - 2025)
·         North America
o    U.S.
o    Canada
·         Europe
o    UK
o    Germany
·         Asia Pacific
o    China
o    India
o    Japan
·         Central & South America
o    Brazil
o    Mexico
·         Middle East & Africa
o    South Africa

Access Full Press Release of this Report:

About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/


Liver Diseases Therapeutics Market Size To Reach USD 7,498.0 Million By 2025:Key Participant GlaxoSmithKline plc, Bristol-Mayers Squibb


San Francisco, 03 January ,  Liver Diseases Therapeutics Market Analysis By Product (Antiviral Drugs, Vaccines, Chemotherapy, Targeted Therapy, Immunosuppressants, Immunoglobulins, Corticosteroids), And Segment Forecasts To 2022
The liver diseases therapeutics market had value over USD 7,498.0 million in 2014. The major driving factors are increasing numbers of liver diseases like hepatocellular carcinoma and vast unexploited need of patients with these types of diseases. In addition, increasing geriatric population globally is estimated to augment the market demand in the future period.
Huge expenditure by biotechnology and pharmaceutical industries on R&D and availability of sturdy pipeline are the major expected boosting factors for the growth of liver diseases therapeutics market in future period. Governments’ and big companies’ vaccination program are creating awareness about the illness and prevention is boosting the growth of the market.
The market is bifurcated into products and regions. New products are rapidly being launched boosting the market growth. The growth of the market is boosted by the strategic alliances, joint venture between the major players, and growing awareness of healthcare in the upcoming nations.
Access Full Research Report On Liver Diseases Therapeutics Market  Analysis:
www.grandviewresearch.com/industry-analysis/liver-diseases-therapeutics-market

Nonetheless, risks and side effects linked with existing medication & stringent FDA and other norms approved by the government along with accessibility of varying treatment measures perform as barriers to the industry. The market was dominated by the antiviral drug sector with a value over USD 2631 million in revenue terms in 2014.
Rising population with liver diseases due to increasing number of alcohol consumers is estimated to boost the market share. Alternatively, the antiviral drug is estimated to observer profitable raise of over 8.8% from 2015 to 2022. This is due to the occurrence of drugs in the pipeline.
The market is estimated to be at over USD 12095.0 million by 2022. This is going to happen due to the increasing geriatric population, rising liver ailments like hepatocellular and hepatitis carcinoma along with high requirement for programs on vaccination in developing nations and high spending on growing healthcare in the developed nations.
North America is dominating the global market due to academic and research institutions performing studies related to medical trials. North America had more than 39% share of the global market in 2014 and is anticipated to carry on leading till 2022. Asia Pacific had share over USD 1615.5 million in 2014 and is estimated at CAGR over 8.5% in the future.
Few of the major industries are Abbott Laboratories, Gilead Sciences, Astellas Pharma Inc., GlaxoSmithKline plc, Bristol-Mayers Squibb, and Merck & Co., Inc.
Access Full Press Release of this Report:

About Grand View Research
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, we offer market intelligence studies ensuring relevant and fact-based research across a range of industries, from technology to chemicals, materials and healthcare.
For more information: www.grandviewresearch.com/